News

Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says
Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...
EU Drug Regulator Finds ‘Very Rare’ Ozempic Link to Vision Loss
Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...
Devdiscourse4h
Potential Vision Risks Associated with Novo's Weight-Loss Drugs
The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
BioSpace2d
EU Regulators Confirm Rare Vision Loss Risk for Novo’s Semaglutide
Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...
TCTMD2d
Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says
Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.
Devdiscourse12h
Health Updates: Measles in Texas and Ozempic's Eye Concern
Texas reports no new measles cases for the first time since February, maintaining 742 total cases. Meanwhile, Novo Nordisk's Ozempic is linked to rare serious eye disorders, possibly causing vision ...
India Today2d
European drugs regulator flags rare eye risk with Ozempic use
The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.
Morningstar3d
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory ...